A Model-Informed Drug Discovery and Development Strategy for the Novel Glucose-Responsive Insulin MK-2640 Enabled Rapid Decision Making

Clin Pharmacol Ther. 2020 Jun;107(6):1296-1311. doi: 10.1002/cpt.1729. Epub 2020 Feb 3.


A model-informed drug discovery and development strategy played a key role in the novel glucose-responsive insulin MK-2640's early clinical development strategy and supported a novel clinical trial paradigm to assess glucose responsiveness. The development and application of in silico modeling approaches by leveraging substantial published clinical insulin pharmacokinetic-pharmacodynamic (PKPD) data and emerging preclinical and clinical data enabled rapid quantitative decision making. Learnings can be applied to define PKPD properties of novel insulins that could become therapeutically meaningful for diabetic patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / drug effects*
  • Computer Simulation
  • Decision Making
  • Diabetes Mellitus / drug therapy
  • Drug Development
  • Drug Discovery / methods
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Hypoglycemic Agents / pharmacokinetics
  • Hypoglycemic Agents / pharmacology
  • Insulin / administration & dosage
  • Insulin / analogs & derivatives*
  • Insulin / pharmacokinetics
  • Insulin / pharmacology
  • Models, Biological*


  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • MK-2640